Aurinia Pharmaceuticals (AUPH) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 36.7% versus a gain of 28.6%. Over five years, AUPH leads with a -22.2% price change compared with -57.9% for DNLI. Denali Therapeutics is the larger company by market cap ($3.06 billion vs $2.13 billion), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | DNLI |
|---|---|---|
| Share price | $16.01 | $19.16 |
| Market cap | $2.13B | $3.06B |
| 1-day change | +2.04% | -0.62% |
| YTD return | +0.38% | +16.05% |
| 1-year return | +36.72% | +28.59% |
| 5-year return | -22.17% | -57.95% |
| P/E ratio (TTM) | 6.90 | — |
| Forward P/E | 15.01 | — |
| EPS (TTM) | $2.32 | $-2.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.25 | $27.30 |
| 52-week low | $10.90 | $13.75 |
| Distance from 52-week high | -16.83% | -29.82% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +11.56% | +88.20% |
| Average volume | 1.01M | 1.61M |
| Shares outstanding | 133.05M | 159.85M |
| Employees | 128 | 503 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Healthcare · Biotechnology · 128 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Healthcare · Biotechnology · 503 employees
AUPH vs DNLI FAQ
Which is bigger, Aurinia Pharmaceuticals or Denali Therapeutics?
Denali Therapeutics (DNLI) is larger, with a market capitalization of $3.06B compared with $2.13B for Aurinia Pharmaceuticals (AUPH).
Which stock has performed better over the past year, AUPH or DNLI?
AUPH returned +36.72% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Denali Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.